Vext Science Croissance future
Future contrôle des critères 5/6
Vext Science is forecast to grow earnings and revenue by 111.1% and 34.6% per annum respectively while EPS is expected to grow by 103.3% per annum.
Informations clés
111.1%
Taux de croissance des bénéfices
103.3%
Taux de croissance du BPA
Pharmaceuticals croissance des bénéfices | 18.0% |
Taux de croissance des recettes | 34.6% |
Rendement futur des capitaux propres | n/a |
Couverture par les analystes | Low |
Dernière mise à jour | 29 Oct 2024 |
Mises à jour récentes de la croissance future
Pas de mise à jour
Recent updates
Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 103 | 17 | 11 | N/A | 1 |
12/31/2025 | 58 | 10 | 8 | 7 | 3 |
12/31/2024 | 37 | -1 | 6 | -1 | 4 |
6/30/2024 | 33 | -7 | -1 | 0 | N/A |
3/31/2024 | 34 | -2 | 2 | 4 | N/A |
12/31/2023 | 35 | 4 | 2 | 4 | N/A |
9/30/2023 | 35 | 5 | 4 | 6 | N/A |
6/30/2023 | 34 | 7 | 0 | 5 | N/A |
3/31/2023 | 34 | 9 | -2 | 3 | N/A |
12/31/2022 | 35 | 11 | -3 | 6 | N/A |
9/30/2022 | 37 | 6 | -3 | 8 | N/A |
6/30/2022 | 38 | 6 | 0 | 11 | N/A |
3/31/2022 | 39 | 6 | -10 | 12 | N/A |
12/31/2021 | 37 | 5 | -8 | 11 | N/A |
9/30/2021 | 34 | 5 | -9 | 8 | N/A |
6/30/2021 | 33 | 5 | -8 | 8 | N/A |
3/31/2021 | 30 | 4 | 2 | 6 | N/A |
12/31/2020 | 25 | 2 | -1 | 3 | N/A |
9/30/2020 | 22 | 0 | -2 | 2 | N/A |
6/30/2020 | 20 | 0 | -6 | 1 | N/A |
3/31/2020 | 20 | 0 | -6 | 0 | N/A |
12/31/2019 | 22 | 3 | -6 | 0 | N/A |
9/30/2019 | 23 | 4 | -5 | -1 | N/A |
6/30/2019 | 23 | 5 | -3 | -1 | N/A |
3/31/2019 | 21 | 4 | -1 | 0 | N/A |
12/31/2018 | 18 | 4 | 1 | 2 | N/A |
12/31/2017 | 15 | 4 | N/A | 2 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: VV5 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.8%).
Bénéfices vs marché: VV5 is forecast to become profitable over the next 3 years, which is considered above average market growth.
Croissance élevée des bénéfices: VV5 is expected to become profitable in the next 3 years.
Chiffre d'affaires vs marché: VV5's revenue (34.6% per year) is forecast to grow faster than the German market (5.5% per year).
Croissance élevée des revenus: VV5's revenue (34.6% per year) is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if VV5's Return on Equity is forecast to be high in 3 years time